SCHEMBL145179

SCHEMBL145179

COC(=O)C1=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2C1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 6/20 0.65
▸ FGFR2 P21802 6/20 0.65
▸ FGFR4 P22455 6/20 0.65
▸ FGFR3 P22607 6/20 0.65
▸ SRC P12931 3/20 0.65
▸ PTPRC P08575 3/20 0.49
▸ S100A4 P26447 2/20 0.49
▸ BCHE P06276 1/20 0.49
▸ ACHE P22303 1/20 0.49
▸ CES1 P23141 1/20 0.49
▸ PTGDR2 Q9Y5Y4 1/20 0.48
▸ PTGS2 P35354 2/20 0.47
▸ PPARG P37231 1/20 0.46
▸ MYC P01106 1/20 0.44
▸ MAX P61244 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142246 0.95 FGFR1 (0.65) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL147746 0.81 FGFR1 (0.74) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL143675 0.80 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL147378 0.80 FGFR1 (0.72) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL27218306 0.79 FGFR1 (0.74) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL17969780 0.77 FGFR1 (0.88) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL30338973 0.77 PTGDR2 (0.54) PTGDR2PTGS2MYCMAXALDH1A1
SCHEMBL5935194 0.77 PTGDR2 (0.54) PTGDR2PTGS2MYCMAXALDH1A1
SCHEMBL15229768 0.77 MYC (0.55) PTGDR2PTGS2PPARGMYCMAX
SCHEMBL144476 0.76 FGFR1 (0.74) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback